earn report chang price
food thought time matter
rais pharma outlook year
expect lasergen sequenc product market
biggest upsid fy guidanc side demand strong
stronger us bounc back
us weak due uneas trade polici nois
china guid lower due ministri reorg
 last month
lower om guid bp due fx acquisit invest
thesi updat let clear happen mani us
got way excit post first quarter number posit shift
exacerb beat shouldnt get downbeat post
 number push-out time element impact core
still capital-expenditure bias busi vs tool provid mind
underli core growth still somewher sound
right current macro given increment food headwind
china front key monitor tool capital-expenditure
provid messag chang happen late march thu asid
downshift china ideal manag real
chang manag ate around cost dilut lasergen
fx otherwis much realli differ mind
said tomorrow stock recommend
buy weak year estim come modestli given
lasergen dilut conserv view capit deploy
target also tweak lower one word caution get
bearish skeptic upset energi tear top analyst
see oil possibl id think that good demand
upcom analyst day got interest stay tune
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
 fx hw
 lower outlook china core vs prior
 due china reorg slow purchas instrument food environment test
 rais outlook biopharma vs prior
 lower om bp adjust mm keysight book vs prior adjust
mm keysight bill classifi
 lasergen invest mm yr mm
 tweak ep vs prior
 core report fx tw tw
 remain strong sourc upsid guidanc
 us bit softer due uneas impact trade polici
biopharma remain healthi across busi
 strength lc/m cell analysi strength acg
diagnost appli strength forens environment off-set weak due weak pain manag food
environment weak china
 china reorg ministri food oversight order bit weaker
 expect last month
 food china busi
 littl bit weak uneas trade polici
china weak due reorg
 icpm pushout market realli hot got order
 hw huge order book last year wouldv
 invest mm mm bring lasergen market
 weak due china icpm pushout get
 ultivo market stabl lot runway market expans play replac strategi
 strong growth consum servic
 lunar ny hit mm
million except per share data fy end decemb scienc appli market organ genom organ cross organ measurementtot organ gp less total scienc appli market genom cross op less ep share inc net inc price-to-earnings prem disc may
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america hold
articl articl
time dissemin may et
analyst ross muken luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
